Patents by Inventor Karen Miller-Moslin

Karen Miller-Moslin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer
    Patent number: 8809352
    Abstract: The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of formula (I): or pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Bcl-2 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff
  • Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
    Patent number: 8536168
    Abstract: The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: September 17, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Feng He, Rishi Kumar Jain, Rajesh Karki, Joseph Kelleher, III, John Lei, Luis Llamas, Michael A. Mcewan, Karen Miller-Moslin, Lawrence Bias Perez, Stefan Peukert, Naeem Yusuff
  • Pyridazinyl derivatives as smo inhibitors
    Patent number: 8481542
    Abstract: The present invention relates to compounds of formula I: in which R11 and R12 are defined in the Summary of the Invention; capable of inhibiting the Hedgehog and Smo signaling pathway. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the diagnosis and treatment of pathologies relating to the Hedgehog and Smo signaling pathway, for example, tumor formation, cancer, neoplasia and non-malignant hyperproliferative disorders.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Novartis AG
    Inventors: Feng He, Stefan Peukert, Karen Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu
  • ORGANIC COMPOUNDS AS SMO INHIBITORS
    Publication number: 20120289507
    Abstract: The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Feng HE, Stefan PEUKERT, Karen MILLER-MOSLIN, Naeem YUSUFF, Zhuoliang CHEN, Bharat LAGU
  • SULFONAMIDE COMPOUNDS
    Publication number: 20120165298
    Abstract: The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of formula (I): or pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Bcl-2 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 8, 2010
    Publication date: June 28, 2012
    Applicant: NOVARTIS AG
    Inventors: Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff
  • Organic Compounds and Their Uses
    Publication number: 20100069368
    Abstract: The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
    Type: Application
    Filed: March 13, 2008
    Publication date: March 18, 2010
    Inventors: Miao Dai, Feng He, Rishi Kumar Jain, Rajesh Karki, Joseph Kelleher, John Lei, Luis Llamas, Michael A. Mcewan, Karen Miller-Moslin, Lawrence Bias Perez, Stefan Peukert, Naeem Yusuff
  • Organic Compounds as Smo Inhibitors
    Publication number: 20100041663
    Abstract: The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.
    Type: Application
    Filed: July 15, 2009
    Publication date: February 18, 2010
    Inventors: Feng HE, Stefan Peukert, Karen Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu